Compare Amgen, Inc. (AMGN) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs DuPont de Nemours Inc — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while DuPont de Nemours Inc trades at $132.53 (market cap $18.18B). The key difference: Amgen, Inc. is far larger — about 10.8× DuPont de Nemours Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DD | |
|---|---|---|
Market Cap | $196.12B | $18.18B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $154.59 |
52-Week Low | $271.18 | $87.72 |
Enterprise Value | $241.41B | $20.65B |
Dividend Yield | 2.77% | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DuPont (DD) trades at $134.68, down 0.08% on the day, with a bearish technical signal and negative net income margin of -0.42% for 2025. Recent earnings have consistently beaten estimates, but revenue declined to $6.85B in 2025 from $12.4B in 2024. The company faces a lawsuit over 'forever chemicals' and completed a 3:1 reverse stock split in June 2026, while maintaining dividend payments.
The stock presents a mixed outlook: strong analyst consensus with a $227.20 price target suggests significant upside, but persistent profitability challenges and legal risks weigh on fundamentals. Investment opportunity hinges on earnings turnaround and resolution of regulatory pressures, though current technical weakness and cash flow trends indicate near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
